Group 1 - The core point of the news is that Sihuan Pharmaceutical (0460.HK) has received approval from the National Medical Products Administration of China for six new specifications of its self-developed polylactic acid facial filler, known as "Tongyan Needle," which enhances its market position in the regenerative medical aesthetics sector [1][2] - The newly approved specifications include 60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle, which will enrich the product selection [1] - Sihuan Pharmaceutical is the only domestic company holding compliant "Tongyan Needle" and "Shaonv Needle" regenerative filler products, along with other significant medical aesthetic devices such as botulinum toxin, hydrating needles, and golden micro-needles [2] Group 2 - The "Tongyan Needle" utilizes the core component of L-lactic acid (PLLA) microspheres, achieving both "immediate filling and long-lasting regeneration" effects, with patented technology ensuring uniform particle size and safety [2] - According to a report by CITIC Securities, Sihuan Pharmaceutical's botulinum toxin and other aesthetic products are experiencing rapid growth, with strong demand for the newly launched regenerative products [2] - The medical aesthetics business is expected to continue its rapid growth due to the synergy of multiple products and integrated solutions aimed at medical aesthetic institutions, with a maintained "buy" rating and a target price of 1.6 HKD [2]
四环医药涨超5% 童颜针新增规格获国家药监局批准上市